Goldman Sachs: Maintains "buy" rating on TRIP.COM-S (09961) with a target price of HK$517.
The management of Ctrip Group stated that they expect to become a leading online travel agency (OTA) in Asia in the next five years. They anticipate that by then, the revenue from China and overseas will reach a more balanced ratio of 50% each, instead of the current 65%/35% ratio.
Goldman Sachs released a research report, maintaining a "buy" rating on TRIP.COM-S(09961) with a target price of 517 Hong Kong dollars. Due to the relatively broader domestic consumption and more elastic travel demand, Goldman Sachs maintains a forecast of 16% annual compound growth rate for Ctrip Group from 2024 to 2027.
Goldman Sachs noted that Ctrip Group holds a dominant position in outbound tourism in China and is expanding through its platform. Ctrip Group remains one of Goldman Sachs' top choices in the leisure/tourism sector in China, with forecasted P/E ratios of 13 times and 11 times for the next two years. Ctrip Group management has stated that they expect to become the leading online travel agency (OTA) in Asia within the next five years, with revenue from China and overseas expected to reach a more balanced ratio of 50% / 50% instead of the current 65% / 35%.
Related Articles

US Stock Market Move | Popular Chinese concept stocks collectively rose sharply, with New Oriental Education & Technology Group, Inc. Sponsored ADR (EDU.US) jumping more than 8%.

US Stock Market Move | Gold stock continues to strengthen, Kinross Gold Corporation (KGC.US) rises more than 7%

US Stock Market Move | Omeros Corporation (OMER.US) soars 150% following asset purchase and license agreement with Novo Nordisk A/S Sponsored ADR Class B.
US Stock Market Move | Popular Chinese concept stocks collectively rose sharply, with New Oriental Education & Technology Group, Inc. Sponsored ADR (EDU.US) jumping more than 8%.

US Stock Market Move | Gold stock continues to strengthen, Kinross Gold Corporation (KGC.US) rises more than 7%

US Stock Market Move | Omeros Corporation (OMER.US) soars 150% following asset purchase and license agreement with Novo Nordisk A/S Sponsored ADR Class B.
